Immunoglobulin Fc-fusion proteins part 2: Therapeutic uses and clinical development

BioProcess International

Volumn 12, Issue 10, 2014, Pages

  Linderholm, Angela ^a   Chamow, Steven M ^a  

^a Chamow and Asso Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; AFLIBERCEPT; ALEFACEPT; B CELL ACTIVATING FACTOR; B7 ANTIGEN; BELATACEPT; BIOSIMILAR AGENT; BLISIBIMOD; BLOOD CLOTTING FACTOR; CASPASE 3; CD28 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; FAS LIGAND; FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; INFLIXIMAB; MONOCLONAL ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT GAMMA INTERFERON; RILONACEPT; ROMIPLOSTIM; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TREBANANIB; TUMOR NECROSIS FACTOR ALPHA;

AGE RELATED MACULAR DEGENERATION; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARBOHYDRATE ANALYSIS; CELL DEATH; CELL MIGRATION; DRUG HALF LIFE; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; GLYCOSYLATION; HEMOPHILIA B; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LIGAND BINDING; METASTATIC COLORECTAL CANCER; MYELODYSPLASTIC SYNDROME; PATIENT COMPLIANCE; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RHEUMATOID ARTHRITIS; STOICHIOMETRY; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; UNITED STATES;

EID: 84910686053     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (43)

1. Therapeutic Fc Fusion Proteins. Chamow SM, et al., Eds. Wiley-Blackwell: Hoboken, NJ, 2014.
2. Rath T, et al. Fc-Fusion Proteins and FcRn: Structural Insights for Longer-Lasting and More Effective Therapeutics. Crit. Rev. Biotechnol. 2013: 1-20.
3. Strober BE, Menon K. Alefacept for the Treatment of Psoriasis and Other Dermatologic Diseases. Dermatol. Ther. 20, 2007: 270-276.
4. Scheinfeld N. Alefacept: Its Safety Profile, Off-Label Uses, and Potential As Part of Combination Therapies for Psoriasis. J. Dermatol. Treat. 18, 2007: 197-208.
5. Linsley PS, et al. Binding Stoichiometry of the Cytotoxic T Lymphocyte-Associated Molecule-4 (CTLA-4): A Disulfide-Linked Homodimer Binds Two CD86 Molecules. J. Biolog. Chem. 270(25) 1995: 15417-15424.
6. Korhonen R, Moilanen E. Abatacept, a Novel CD80/86-CD28 T Cell Co-Stimulation Modulator, in the Treatment of Rheumatoid Arthritis. Bas. Clin. Pharmacol. Toxicol. 104(4) 2009: 276-284.
7. Emamaullee J, et al. Costimulatory Blockade with Belatacept in Clinical and Experimental Transplantation: A Review. Exp. Opin. Biol. Ther. 9(6) 2009: 789-796.
8. Hoffman HM, et al. Long-Term Efficacy and Safety Profile of Rilonacept in the Treatment of Cryopryin-Associated Periodic Syndromes: Results of a 72-Week Open-Label Extension Study. Clin. Ther. 34(10) 2012: 2091-2103.
9. Holash J, et al. VEGF-Trap: A VEGF Blocker with Potent Antitumor Effects. Proc. Nat. Acad. Sci. USA 99(17) 2002: 11393-11398.
10. Cines D, et al. Romiplostim. Nat. Rev. Drug Disc. 7(11) 2008: 887-888.
11. Kuter D, et al. Efficacy of Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura: A Double-Blind Randomised Controlled Trial. Lancet 371(9610) 2008: 395-403.
12. Scallon B, et al. Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists. J. Pharmacol. Exper. Therapeut. 301(2) 2002: 418-426.
13. Hamilton K, Clair EW. Tumour Necrosis Factor-Alpha Blockade: A New Era for Effective Management of Rheumatoid Arthritis. Exp. Opin. Pharmacother. 1(5) 2000: 1041-1052.
14. Sandborn WJ, et al. Etanercept for Active Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterol. 121(5) 2001: 1088-1094.
15. Van den Brande JM, et al. Infliximab but Not Etanercept Induces Apoptosis in Lamina Propria T-Lymphocytes from Patients with Crohn's Disease. Gastroenterol. 124(7) 2003: 1774-1785.
16. Gater A, et al. Haemophilia B: Impact on Patients and Economic Burden of Disease. Thrombosis Haemostasis 106(3) 2011: 398-404.
17. Powell JS, et al. Safety and Prolonged Activity of Recombinant Factor VIII Fc Fusion Protein in Hemophilia A Patients. Blood 119(13) 2012: 3031-3037. 3
18. Peters RT, et al. Prolonged Activity of Factor IX As a Monomeric Fc Fusion Protein. Blood 115(10) 2010: 2057-2064.
19. Sandberg H, et al. Structural and Functional Characteristics of the B-Domain-Deleted Recombinant Factor VIII Protein, r-VIII SQ. Thrombosis Haemostasis 85(1) 2001: 93-100.
20. Mahlangu J, et al. Phase 3 Study of Recombinant Factor VIII Fc Fusion Protein in Severe Hemophilia A. Blood 123(3) 2014: 317-325.
21. Eskander RN, Tewari KS. Incorporation of Anti-Angiogenesis Therapy in the Management of Advanced Ovarian Carcinoma: Mechanistics, Review of Phase III Randomized Clinical Trials, and Regulatory Implications. Gynecol. Oncol. 132(2) 2014: 496-505.
22. Stohl W. Therapeutic Targeting of the BAFF/APRIL Axis in Systemic Lupus Erythematosus. Exp. Opin. Therapeut. Targets 18(4) 2014: 473-489.
23. Nauck M, et al. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care 37(8) 2014: 2149-2158.
24. Wrighton NC, et al. Small Peptides As Potent Mimetics of the Protein Hormone Erythropoietin. Science 273(5274) 1996: 458-464.
25. Sathyanarayana P, et al. CNTO 530 Functions As a Potent EPO Mimetic Via Unique Sustained Effects on Bone Marrow Proerythroblast Pools. Blood 113(20) 2009: 4955-4962.
26. Dorai H, et al. Development of Mammalian Production Cell Lines Expressing CNTO736, a Glucagon Like Peptide-1-MIMETIBODY: Factors that Influence Productivity and Product Quality. Biotechnol. Bioeng. 103(1) 2009: 162-176.
27. Tuettenberg J, et al. Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of APG101, a CD95-Fc Fusion Protein, in Healthy Volunteers and Two Glioma Patients. Internat. Immunopharmacol. 13(1) 2012: 93-100.
28. Gillies SD, et al. Bi-Functional Cytokine Fusion Proteins for Gene Therapy and Antibody-Targeted Treatment of Cancer. Cancer Immunol. Immunother. 51(8) 2002: 449-460.
29. Muda M, et al. Therapeutic Assessment of SEED: A New Engineered Antibody Platform Designed to Generate Mono- and Bispecific Antibodies. PEDS 24(5) 2011: 447-454.
30. Nagashima H, et al. TNF Receptor II Fusion Protein with Tandemly Repeated Fc Domains. J. Biochem. 149(3) 2011: 337-346.
31. Mekhaiel DN, et al. Polymeric Human Fc-Fusion Proteins with Modified Effector Functions. Scientif. Reports 19 October 2011: 124.
32. Kaveri SV, et al. Natural IgM in Immune Equilibrium and Harnessing Their Therapeutic Potential. J. Immunol. 188(3) 2012: 939-945.
33. Peipp M, et al. Effector Mechanisms of Therapeutic Antibodies Against ErbB Receptors. Curr. Opin. Immunol. 20(4) 2008: 436-443.
34. Nelson AL. Antibody Fragments: Hope and Hype. MAbs 2(1) 2010: 77-83.
35. West AP Jr., et al. Single-Chain Fv-Based Anti-HIV Proteins: Potential and Limitations. J. Virol. 86(1) 2012: 195-202.
36. Löfblom J, et al. Non-Immunoglobulin Based Protein Scaffolds. Curr. Opin. Biotechnol. 22(6) 2011: 843-848.
37. Bakema JE, van Egmond M. Immunoglobulin A: A Next Generation of Therapeutic Antibodies? MAbs 3(4) 2011: 352-361.
38. Ammann JU, et al. Detection of Weak Receptor-Ligand Interactions Using IgM and J-Chain-Based Fusion Proteins. Euro. J. Immunol. 42(5) 2012: 1354-1356.
39. Tan Q, et al. Characterization and Comparison of Commercially Available TNF Receptor 2-Fc Fusion Protein Products. MAbs 4(6) 2012: 761-774.
40. Brockhaus M, et al. Human TNF Receptor Fusion Protein. US PTO #8063182, 22 November 2011.
41. Daghlian M. Amgen Issued New Patent on RA Drug Enbrel. The Burrill Report 1 December 2011; www.burrillreport.com/article-amgen-issued-new-patent-on-ra-drug-enbrel.html.
42. Maity S, et al. A Non-Innovator Version of Etanercept for Treatment of Arthritis. Biologicals 39(6) 2011: 384-395.
43. Yang T, et al. A Variant of TNFR2-Fc Fusion Protein Exhibits Improved Efficacy in Treating Experimental Rheumatoid Arthritis. PLoS Comput. Biol. 6(2) 2010.